CA2889537C - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome - Google Patents
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome Download PDFInfo
- Publication number
- CA2889537C CA2889537C CA2889537A CA2889537A CA2889537C CA 2889537 C CA2889537 C CA 2889537C CA 2889537 A CA2889537 A CA 2889537A CA 2889537 A CA2889537 A CA 2889537A CA 2889537 C CA2889537 C CA 2889537C
- Authority
- CA
- Canada
- Prior art keywords
- usher
- compound
- salt
- acid
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718593P | 2012-10-25 | 2012-10-25 | |
| US61/718,593 | 2012-10-25 | ||
| US201361775376P | 2013-03-08 | 2013-03-08 | |
| US61/775,376 | 2013-03-08 | ||
| PCT/US2013/066938 WO2014066835A1 (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2889537A1 CA2889537A1 (en) | 2014-05-01 |
| CA2889537C true CA2889537C (en) | 2017-12-12 |
Family
ID=50545355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2889537A Active CA2889537C (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2912038B1 (enExample) |
| JP (1) | JP6290910B2 (enExample) |
| AU (1) | AU2013334138B2 (enExample) |
| CA (1) | CA2889537C (enExample) |
| ES (1) | ES2693166T3 (enExample) |
| IL (1) | IL238287B (enExample) |
| PL (1) | PL2912038T3 (enExample) |
| TR (1) | TR201816028T4 (enExample) |
| WO (1) | WO2014066835A1 (enExample) |
| ZA (1) | ZA201502654B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5902293B2 (ja) | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| CA2889494C (en) * | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| EP4178580B1 (en) | 2020-07-09 | 2025-11-05 | Usher III Initiative, Inc. | Bf 844 for use in the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295550A3 (en) * | 2001-04-30 | 2011-12-14 | Vertex Pharmaceuticals Incorporated | Crystal structures of GSK-3beta protein and protein complexes and their use |
| ATE554087T1 (de) * | 2004-10-29 | 2012-05-15 | Abbott Lab | Neue kinaseinhibitoren |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| WO2009062118A2 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| AU2009262068C1 (en) * | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| JP5902293B2 (ja) * | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| CA2889494C (en) * | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
-
2013
- 2013-10-25 JP JP2015539867A patent/JP6290910B2/ja active Active
- 2013-10-25 ES ES13849803.5T patent/ES2693166T3/es active Active
- 2013-10-25 CA CA2889537A patent/CA2889537C/en active Active
- 2013-10-25 AU AU2013334138A patent/AU2013334138B2/en active Active
- 2013-10-25 TR TR2018/16028T patent/TR201816028T4/tr unknown
- 2013-10-25 WO PCT/US2013/066938 patent/WO2014066835A1/en not_active Ceased
- 2013-10-25 EP EP13849803.5A patent/EP2912038B1/en active Active
- 2013-10-25 PL PL13849803T patent/PL2912038T3/pl unknown
-
2015
- 2015-04-14 IL IL238287A patent/IL238287B/en active IP Right Grant
- 2015-04-20 ZA ZA2015/02654A patent/ZA201502654B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL238287B (en) | 2018-07-31 |
| AU2013334138A1 (en) | 2015-05-07 |
| HK1214263A1 (en) | 2016-07-22 |
| ZA201502654B (en) | 2016-07-27 |
| JP2015535256A (ja) | 2015-12-10 |
| PL2912038T3 (pl) | 2019-02-28 |
| EP2912038A1 (en) | 2015-09-02 |
| AU2013334138B2 (en) | 2017-07-27 |
| JP6290910B2 (ja) | 2018-03-07 |
| TR201816028T4 (tr) | 2018-11-21 |
| EP2912038B1 (en) | 2018-08-15 |
| ES2693166T3 (es) | 2018-12-07 |
| CA2889537A1 (en) | 2014-05-01 |
| WO2014066835A1 (en) | 2014-05-01 |
| EP2912038A4 (en) | 2016-04-20 |
| IL238287A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4034104B1 (en) | Methods and compounds for restoring mutant p53 function | |
| US9783545B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| JP6291502B2 (ja) | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 | |
| US10307422B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| AU2013334138B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | |
| US8765762B2 (en) | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome | |
| HK1214263B (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| HK1214180B (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
| HK1195507A (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150423 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241018 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251017 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |